Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 3, 2023

Advances in the Relationship between Β-Amyloid Neurotoxicity and Blood-Brain Barrier Dysfunction in Diabetic Encephalopathy

Download as PDF

DOI: 10.23977/medsc.2023.040313 | Downloads: 13 | Views: 358

Author(s)

Huitao Guo 1, Youcai Yuan 1

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China

Corresponding Author

Youcai Yuan

ABSTRACT

DE is one of them important co-morbidities of DM, which is a disease with cognitive dysfunction as the main manifestation based on DM, and the prevention of DE has become an urgent public health and social problem in China and worldwide. This series of pathological changes of Aβ becomes the dominant link in the pathogenesis of DE. This series of pathological changes in Aβ becomes the dominant link in the pathogenesis of DE. The abnormal aggregation of Aβ depends on the normal function of BBB, and BBB dysfunction will exacerbate the deposition of Aβ. Therefore, understanding the relationship between abnormal Aβ deposition and BBB is crucial for us to understand the pathogenesis of DE and to formulate treatment plans. A brief review of the relationship between the two is presented.

KEYWORDS

Diabetic encephalopathy, Β-amyloid, Diabetes mellitus, Cognitive dysfunction

CITE THIS PAPER

Huitao Guo, Youcai Yuan, Advances in the Relationship between Β-Amyloid Neurotoxicity and Blood-Brain Barrier Dysfunction in Diabetic Encephalopathy. MEDS Clinical Medicine (2023) Vol. 4: 101-106. DOI: http://dx.doi.org/10.23977/medsc.2023.040313.

REFERENCES

[1] Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer's disease. Neurobiol Dis. 2017;107:41-56.
[2] Cai Z, Qiao PF, Wan CQ, et al. Role of Blood-Brain Barrier in Alzheimer's Disease. J Alzheimers Dis. 2018;63(4):1223-1234.
[3] Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9):1937-1942.
[4] Umegaki H, Hayashi T, Nomura H, et al. Cognitive dysfunction: an emerging concept of a new diabetic complication in the elderly. Geriatr Gerontol Int. 2013;13(1):28-34.
[5] Yoneda S, Hara H, Hirata A, et al. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol. 2005;49(2):106-108.
[6] Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010;107(15):7036-7041.
[7] Menendez-Gonzalez M, Padilla-Zambrano HS, Alvarez G, et al. Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease. Front Aging Neurosci. 2018;10:100.
[8] Saretz S, Basset G, Useini L, et al. Modulation of γ-Secretase Activity by a Carborane-Based Flurbiprofen Analogue. Molecules. 2021;26(10):2843.
[9] Gireud-Goss M, Mack AF, McCullough LD, et al. Cerebral Amyloid Angiopathy and Blood-Brain Barrier Dysfunction. Neuroscientist. 2021; 27(6):668-684.
[10] Kumar K, Kumar A, Keegan RM, et al. Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease. Biomed Pharmacother. 2018; 98: 297-307.
[11] Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease andother disorders. Nat Rev Neurosci. 2011; 12(12):723-738.
[12] Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010; 330(6012):1774.
[13] Wang D, Chen F, Han Z. Relationship Between Amyloid-β Deposition and Blood-Brain Barrier Dysfunction in Alzheimer's Disease. Front Cell Neurosci. 2021;15:695479.
[14] Chan Y, Chen W, Wan W, et al. Aβ1-42 oligomer induces alteration of tight junction scaffold proteins via RAGE-mediated autophagy in bEnd.3 cells. Exp Cell Res. 2018;369(2):266-274.
[15] Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease [published correction appears in Nat Rev Neurol. 2016 Apr;12(4):248]. Nat Rev Neurol. 2015;11(8):457-470.
[16] Ridler C. Alzheimer disease: BACE1 inhibitors block new Aβ plaque formation. Nat Rev Neurol. 2018;14(3):126.
[17] Montagne A, Zhao Z, Zlokovic BV. Alzheimer's disease: A matter of blood-brain barrier dysfunction?. J Exp Med. 2017;214(11):3151-3169.
[18] Storck SE, Hartz AMS, Bernard J, et al. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. Brain Behav Immun. 2018; 73:21-33.
[19] Gali CC, Fanaee-Danesh E, Zandl-Lang M, et al. Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-β in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. Mol Cell Neurosci. 2019; 99:103390.
[20] Osgood D, Miller MC, Messier AA, et al. Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier. Neurobiol Aging. 2017; 57:178-185.
[21] Swaminathan SK, Ahlschwede KM, Sarma V, et al. Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab. 2018; 38(5):904-918.
[22] Wang X, Lopez OL, Sweet RA. Genetic determinants of disease progression in Alzheimer’s disease. J Alzheimers Dis 2015; 43(2):649-655.
[23] Salazar SV, Cox TO, Lee S. Alzheimer’s disease risk factor Pyk2 mediates amyloid-β-induced synaptic dysfunction and loss. J Neurosci 2019; 39(4):758-772.
[24] Brys Z, Pluhar A, Kis JT. Network analysis of neurotransmitter related human kinase genes: possible role of SRC, RAF1, PTK2B? Neuropsychopharmacol Hung 2013; 15(3):165-171.
[25] Grossi M, Bhattachariya A, Nordström I, et al. Pyk2 inhibition promotes contractile differentiation in arterial smooth muscle. J Cell Physiol 2017; 232(11): 3088-3102.
[26] Marques MA, Kulstad JJ, Savard CE, et al. Peripheral amyloid-β levels regulate amyloid-β clearance from the central nervous system. J Alzheimers Dis 2009; 16(2): 325–329.
[27] Deane R, Bell RD, Sagare A, et al. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2009;8(1):16-30.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4411
Visits: 194294

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.